TETRAPHASE PHARMACEUTICALS INC TTPH Cash Flow

Tetraphase pharmaceuticals inc (TTPH)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Operating activities
Net loss
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-72,158	-74,153	-84,602	-106,870	-114,752	0	0	0	-73,135	-70,068	-78,944	-83,189	-85,624	-81,786	-74,205	-66,742	-57,494	-53,405	-40,368	-29,636	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
544	633	739	744	661	576	473	467	457	431	0	0	0	270	263	228	193	163	137	131	124	117	110	118	129	0	0	0
Non-cash interest expense related to notes payable
-	621	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred financing costs and debt discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94	134	187	249	226	263	297	328	342	0	0	0
Accretion of final interest payment on term loans
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45	64	90	122	115	140	164	187	199	0	0	0
Fair value adjustment of warrants and investor right obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Stock-based compensation expense
4,192	6,435	8,852	11,197	12,881	13,129	12,485	12,091	11,858	11,963	0	0	0	13,938	11,884	12,952	11,616	9,836	9,742	6,931	5,230	0	0	0	-	-	0	0
Gain from modification of operating lease
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on asset disposal
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	-3	-3	-3	-2	0	0	0	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
-112	-772	-888	-1,384	-1,396	-2,379	-968	430	1,510	2,864	0	0	0	-2,321	-441	-1,635	693	1,113	2,080	3,462	1,752	-181	-1,569	105	-746	0	0	0
Inventory
-1,559	847	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-1,234	-569	-2,583	-2,985	-4,518	-3,708	-192	914	3,101	-200	0	0	0	4,090	2,292	3,792	1,514	-10	1,180	1,700	1,199	156	1,114	1,118	154	0	0	0
Accounts payable
-715	-781	-1,702	-40	-907	-2,096	-5,439	-4,799	4	2,751	0	0	0	1,885	-3,245	-4,021	-1,249	-2,002	-938	1,585	2,224	822	4,761	1,893	310	0	0	0
Accrued expenses and other liabilities
-4,023	-5,851	-590	3,100	3,113	-909	-3,741	-3,427	-5,665	4,816	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and accrued final interest payment on term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	1,048	2,724	2,110	3,190	0	0	0
Deferred revenue
-	-6	-9	-109	-7,479	-654	-773	-1,439	6,628	-595	0	0	0	692	670	360	651	361	524	1,018	166	-218	0	-333	-607	0	0	0
Operating lease right-of-use assets
1,420	1,402	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities
-1,387	-1,352	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-60,428	-64,971	-72,983	-76,707	-75,478	-72,375	-64,972	-57,623	-51,473	-41,785	-34,965	-24,506	0	0	0
Net cash used in operating activities
-54,706	-63,670	-69,156	-66,187	-60,853	-59,628	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investing activities
Proceeds from sale of property and equipment
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
-	108	207	222	219	204	191	183	350	771	0	0	0	333	299	859	838	721	849	213	191	258	163	148	129	0	0	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-333	-299	-859	-838	-721	-849	-213	-191	-258	-163	-148	-129	0	0	0
Proceeds from sale of common stock, net of underwriter discounts and issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	119,404	0	0	0
Net cash provided by (used in) investing activities
706	478	-1,945	-4,972	-4,969	-4,954	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing activities
Proceeds from issuance of term loan payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,000	0	0	0
Repayment of debt, including final payment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,646	6,026	7,646	9,227	6,126	6,255	5,949	5,082	4,232	0	0	0
Proceeds from sale of common stock and prefunded warrants under a concurrent private placement and registered direct offering, net of issuance costs
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock under "at-the-market" equity offering sales agreement, net of issuance costs
-	-	-	-	-	-	-	-	-	92,536	0	0	0	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from issuance of stock under stock plans
0	-	-	-	-	459	615	678	753	610	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
0	-	-	-	-	36,447	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash, cash equivalents and restricted cash
-61,413	-86,537	-72,451	-39,748	-29,606	-28,135	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	378	1,502	3,385	162,415	242,661	239,932	236,494	76,144	39,896	40,103	45,961	118,268	0	0	0
Net decrease in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-60,383	-63,768	-70,457	84,870	166,462	166,708	171,309	18,330	-11,835	-1,845	10,848	93,633	0	0	0
Supplemental cash flow disclosures from investing activities
Cash paid for interest
-	1,955	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	363	707	604	1,071	945	874	1,019	1,146	1,142	0	0	0
Issuance costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Fair value of warrants issued in connection with issuance of term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	115	0	0	0
Conversion of convertible preferred stock into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	79,841	0	0	0
Reclassification of warrant liability to additional paid-in-capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	462	0	0	0